Journal
FUTURE ONCOLOGY
Volume 18, Issue 35, Pages 3913-3927Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0758
Keywords
breakthrough cancer pain; medical oncology; quality of life; rapid-onset opioids; transmucosal fentanyl
Categories
Funding
- Angelini Pharma Espana S.L.U.
- Fundacion ECO (Fundacion para la Excelencia y la Calidad de la Oncologia, Madrid, Spain)
Ask authors/readers for more resources
This study evaluated the quality of life in patients with BTcP in Spanish medical oncology departments. The results showed that individualized BTcP therapy could improve patients' QoL.
Aim: To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. Patients & methods: In a prospective, observational, multicenter study, we assessed QoL using the EQ-5D-5L instrument at baseline and after 15 and 30 days of individualized BTcP therapy, as well as BTcP characteristics and treatment. Results: Patients (n = 118) were mainly women, over 64 years old and with advanced cancer. QoL improved at 15 (p = 0.013) and 30 days (p = 0.011) versus baseline. Individualized BTcP therapy consisted mostly of rapid-onset opioids (transmucosal fentanyl at doses of 67-800 mu g) according to the physician evaluation. BTcP improved, including statistically significant reductions in intensity, duration, number of episodes in the last 24 h and time to onset of BTcP relief. Conclusion: QoL increased after individualized pain therapy in patients with advanced cancer and BTcP in medical oncology departments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available